Home / Market News / $BBIO
benzinga Corporate Catalyst Impact 75/100 ● positive

Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima

Oct 5, 2026, 11:32 AM UTC · Primary ticker $BBIO

BridgeBio announced positive exploratory cardiac data from the 12-month interim analysis of its Phase 3 FORTIFY trial for BBP-418 in LGMD2I/R9. The data showed significant improvements in cardiac injury markers and left ventricular ejection fraction compared to placebo, suggesting BBP-418's potential as a disease-modifying therapy.

BridgeBio presented encouraging exploratory cardiac data from the interim analysis of its Phase 3 FORTIFY trial for BBP-418, a drug targeting Limb-Girdle Muscular Dystrophy Type 2I/R9. The data indicates BBP-418 significantly reduced heart muscle injury markers and stabilized/improved cardiac function compared to placebo. This is a significant positive development as cardiac complications are a major concern in this patient population, and the findings suggest BBP-418 could be a disease-modifying therapy. With the drug under FDA Priority Review and a PDUFA date in November 2026, these positive interim results could bolster its approval prospects and long-term market potential, making BBIO an attractive opportunity for investors looking at long-term growth in the rare disease space.

$BBIO positive Positive clinical trial data for key pipeline asset
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.